Abis.Mi
ABIS.MI is a biotechnology company focused on healthcare diagnostics, generating revenue primarily through the development and sale of diagnostic solutions.
Business. ABIS.MI is a biotechnology company focused on healthcare diagnostics, generating revenue primarily through the development and sale of diagnostic solutions.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ABIS.MI is a biotechnology company focused on healthcare diagnostics, generating revenue primarily through the development and sale of diagnostic solutions.
ABIS.MI maintains a strong liquidity position, with a current ratio of 7.74 and cash and equivalents of 1,342,610 EUR, indicating a robust ability to meet short-term obligations. The company's debt-to-equity ratio is 0.07, suggesting a conservative capital structure with minimal reliance on debt financing. Free cash flow of 996,480 EUR and operating cash flow of 1,992,220 EUR further support its financial flexibility.
Profitability metrics for ABIS.MI are strong, with a return on equity of 15.95% and a return on assets of 13.75%, both exceeding the typical thresholds for financial performance in the biotechnology and medical research industry. The company's operating income of 1,797,360 EUR and net income of 2,006,280 EUR reflect solid operational efficiency and cost management.
ABIS.MI's revenue is concentrated in a single business segment, as disclosed in its financial reporting, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may expose the company to higher concentration risk, particularly in the healthcare diagnostics market.
The company's growth trajectory is supported by consistent revenue and net income, with no specific growth rate provided in the available data. Analysts have assigned a mean price target of 4.20 EUR, with a median and high price target also at 4.20 EUR, indicating a consensus on valuation. The mean recommendation of 2.00 suggests a generally positive outlook, though no strong buy ratings have been issued.
Risk factors for ABIS.MI are currently low, with no immediate filing-based liquidity or dilution flags detected. The company's low dilution potential and stable capital structure reduce the risk of equity dilution in the near term. However, the lack of geographic and segment diversification remains a potential vulnerability.
Recent events and filings for ABIS.MI do not indicate any material changes in the company's financial or operational status. The absence of recent significant events or disclosures suggests a stable and predictable business environment.
- ABIS.MI has a strong liquidity position with a current ratio of 7.74 and significant cash reserves.
- The company's profitability metrics, including a 15.95% return on equity, are robust and exceed industry norms.
- ABIS.MI's revenue is concentrated in a single business segment, increasing exposure to market-specific risks.
- Analysts have assigned a mean price target of 4.20 EUR, with a generally positive outlook but no strong buy ratings.
- The company's low debt-to-equity ratio and absence of dilution flags suggest a conservative and stable capital structure.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ABIS.MI Market data — financials · 2026-05-27
- Arterra Bioscience SpA Market data — analyst estimates · 2026-05-27